/
/
/

Accent Microcell Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
-21%21%32%
-56%53%33%
---123%
22%23%22%19%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
ACCENTMIC-SM
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,793.5₹425150 Cr38.778.2958.23₹11479 Cr
10,005₹266265 Cr91.0334.04128.41₹2568 Cr
4,683.3₹176301 Cr8314.04106.21₹2163 Cr
2,318.6₹125352 Cr93.568.1733.94₹889 Cr
1,193₹123591 Cr27.399.4262.53₹5040 Cr
1,365₹114351 Cr40.8411.0859.2₹4196 Cr
1,390₹112474 Cr38.8210.8652.6₹3879 Cr
2,484.5₹102315 Cr45.6217.2376.26₹1913 Cr
1,710.1₹97757 Cr26.3317.9596.84₹3505 Cr
2,026.2₹92007 Cr16.6430.95154.35₹5333 Cr
609.8₹1510 Cr34.42—20.22₹44 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Miscellaneous Expenses not written off
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
——————
₹24 Cr₹21 Cr₹21 Cr₹13 Cr₹13 Cr₹4 Cr
₹251 Cr₹174 Cr₹143 Cr₹37 Cr₹19 Cr₹22 Cr
₹251 Cr₹174 Cr₹143 Cr₹37 Cr₹19 Cr₹22 Cr
₹275 Cr₹195 Cr₹164 Cr₹50 Cr₹32 Cr₹27 Cr
₹34 L₹86 L₹1 Cr₹2 Cr₹3 Cr₹4 Cr
₹0₹0₹2 L₹3 Cr₹4 Cr₹14 Cr
-₹13 L₹89 L₹86 L₹89 L₹1 Cr₹1 Cr
₹2 Cr₹1 Cr₹79 L₹23 L₹42 L₹25 L
₹3 Cr₹3 Cr₹3 Cr₹7 Cr₹9 Cr₹19 Cr
——————
₹20 Cr₹18 Cr₹19 Cr₹35 Cr₹30 Cr₹18 Cr
₹20 Cr₹11 Cr₹8 Cr₹4 Cr₹9 Cr₹6 Cr
₹0₹0₹10 Cr₹15 Cr₹14 Cr₹10 Cr
₹17 Cr₹23 Cr₹10 Cr₹3 Cr₹44 L₹37 L
₹56 Cr₹52 Cr₹46 Cr₹56 Cr₹54 Cr₹35 Cr
₹334 Cr₹250 Cr₹213 Cr₹113 Cr₹95 Cr₹81 Cr
₹20 Cr₹5 Cr₹4 Cr₹0₹0₹0
₹88 L₹2 Cr₹13 Cr₹23 Cr₹24 Cr₹31 Cr
——————
₹94 Cr₹89 Cr₹66 Cr₹64 Cr₹59 Cr₹55 Cr
₹41 Cr₹41 Cr₹37 Cr₹32 Cr₹28 Cr₹24 Cr
₹53 Cr₹48 Cr₹29 Cr₹31 Cr₹30 Cr₹30 Cr
₹102 Cr₹13 Cr₹2 Cr₹0₹0₹0
₹0₹0₹0₹15,000₹0₹0
₹0₹0₹0₹15,000₹0₹0
₹11 Cr₹13 Cr₹11 Cr₹2 Cr₹57 L₹56 L
₹46 L₹4 L₹0₹0₹0₹0
₹167 Cr₹74 Cr₹41 Cr₹33 Cr₹31 Cr₹31 Cr
——————
₹32 Cr₹34 Cr₹33 Cr₹42 Cr₹40 Cr₹32 Cr
₹91 Cr₹65 Cr₹54 Cr₹30 Cr₹17 Cr₹13 Cr
₹20 Cr₹51 Cr₹72 Cr₹2 Cr₹3 Cr₹1 Cr
₹4 Cr₹3 Cr₹2 Cr₹3 Cr₹4 Cr₹3 Cr
₹20 Cr₹23 Cr₹10 Cr₹3 Cr₹49 L₹1 Cr
₹168 Cr₹176 Cr₹172 Cr₹80 Cr₹64 Cr₹50 Cr
₹111 Cr₹124 Cr₹126 Cr₹24 Cr₹10 Cr₹15 Cr
₹0₹0₹0₹6 L₹0₹0
₹334 Cr₹250 Cr₹213 Cr₹113 Cr₹95 Cr₹81 Cr
₹115₹93₹78₹39₹25₹62
₹115₹93₹78₹39₹8₹21

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
₹58 Cr₹44 Cr₹37 Cr₹15 Cr₹8 Cr₹6 Cr
₹4 Cr₹73 L₹6 Cr₹6 Cr₹7 Cr₹3 Cr
-₹30 Cr-₹9 Cr-₹25 Cr-₹11 Cr₹2 Cr-₹3 Cr
₹32 Cr₹36 Cr₹18 Cr₹10 Cr₹17 Cr₹6 Cr
₹19 Cr₹25 Cr₹11 Cr₹8 Cr₹15 Cr₹5 Cr
-₹49 Cr-₹9 Cr-₹82 Cr-₹4 Cr-₹4 Cr-₹6 Cr
₹36 Cr-₹14 Cr₹72 Cr-₹4 Cr-₹10 Cr-₹2 Cr
₹6 Cr₹2 Cr₹1 Cr-₹79 L₹90 L-₹3 Cr
₹4 Cr₹2 Cr₹31 L₹1 Cr₹20 L₹4 Cr
₹9 Cr₹4 Cr₹2 Cr₹31 L₹1 Cr₹20 L

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)625.50
Volume (₹)1.12 L
High (₹)630.05
Upper Circuit755.10
Low (₹)601.00
Lower Circuit503.40
Prev Close629.25
52W High (₹)731.70
Price609.80
52W Low (₹)280.00

Share Market Cap & Key Ratios Overview

M.Cap (₹)1509.51 Cr
Div. Yield (%)0.16
PE Ratio34.42
Debt to Equity0.00
Price to Book3.09
Book Value114.84
EPS (TTM)18.28
Face Value10.00
ROE (%)18.65

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
ACCENTMIC-SMNSE
LTP
1W Low
1W High
Market cap (₹)
1793.5+15.8 (0.89%)
1722
1810.40
4,25,150Cr
10005+225 (2.30%)
9863
10067
2,66,265Cr
4683.3+69.9 (1.52%)
4553
4698.50
1,76,301Cr
2318.6-86.9 (-3.61%)
2252.40
2441.90
1,25,352Cr
1193-52.5 (-4.22%)
1189.20
1266.60
1,23,591Cr
1365+13 (0.96%)
1336.70
1376.70
1,14,351Cr
1390+11.1 (0.80%)
1364.60
1400.80
1,12,474Cr
2484.5-8.3 (-0.33%)
2457.90
2512.30
1,02,315Cr
1710.1+28.7 (1.71%)
1656.20
1713.80
97,757Cr
2026.2+15.2 (0.76%)
1988.90
2062.10
92,007Cr
609.8-29.2 (-4.57%)
601
655
1,510Cr

Accent Microcell Ltd Annual Results Key Takeaways

Basis: Consolidated annual results.

Accent Microcell Ltd Quaterly Results Key Takeaways